
AC Immune (ACIU) Stock Forecast & Price Target
AC Immune (ACIU) Analyst Ratings
Bulls say
AC Immune SA's pipeline showcases promising developments in neurodegenerative disease therapies, particularly the PD active immunotherapy ACI-7104.056, which has exhibited a significant 20-fold increase in antibodies against pathogenic aSyn variants, highlighting its potential efficacy. Additionally, the company’s NLRP3 program is poised for increased interest, especially with the forthcoming results from the EVOKE trial focusing on Alzheimer's Disease, which could further validate its therapeutic approach. These advancements, combined with a strategic emphasis on safe delivery methods for monoclonal antibodies, position AC Immune favorably within the evolving Alzheimer’s treatment landscape, enhancing its outlook for future growth and success.
Bears say
AC Immune SA reported a net operating loss of CHF 16.2 million for the quarter, highlighting ongoing financial challenges. The company is exposed to various risks typical of the biopharmaceutical sector, including potential unfavorable clinical outcomes, regulatory uncertainties, and the complexities of navigating a price-sensitive commercial landscape. These factors contribute to a negative outlook for the company's stock, as they could impact future revenue generation and profitability prospects.
This aggregate rating is based on analysts' research of AC Immune and is not a guaranteed prediction by Public.com or investment advice.
AC Immune (ACIU) Analyst Forecast & Price Prediction
Start investing in AC Immune (ACIU)
Order type
Buy in
Order amount
Est. shares
0 shares